The company is developing disruptive technology to help diagnose the root causes of Functional Gastrointestinal Disorders (‘FGIDs’) that afflict more than 60 million people annually in the US alone.
Its technology is designed to address clinical and market needs to dramatically improve care for patients, providers and institutions; and to reduce costs associated with this disease.
